Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

57 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Low tristetraprolin expression activates phenotypic plasticity and primes transition to lethal prostate cancer in mice.
Morel KL, Germán B, Hamid AA, Nanda JS, Linder S, Bergman AM, van der Poel H, Hofland I, Bekers EM, Trostel SY, Burkhart DL, Wilkinson S, Ku AT, Kim M, Kim J, Ma D, Plummer JT, You S, Su XA, Zwart W, Sowalsky AG, Sweeney CJ, Ellis L. Morel KL, et al. Among authors: hofland i. J Clin Invest. 2024 Nov 19:e175680. doi: 10.1172/JCI175680. Online ahead of print. J Clin Invest. 2024. PMID: 39560993
Away from definition and back to the clinic - as response to Kumar et al, 'Evidence is not sufficient to declare the tubal gland conglomerates as salivary.'.
Pringle S, Bikker FJ, Vogel W, de Bakker BS, Hofland I, van der Vegt B, Bootsma H, G M Kroese F, Vissink A, Valstar M. Pringle S, et al. Among authors: hofland i. Radiother Oncol. 2023 Oct 28:109959. doi: 10.1016/j.radonc.2023.109959. Online ahead of print. Radiother Oncol. 2023. PMID: 39492512 No abstract available.
Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial.
Nederlof I, Isaeva OI, de Graaf M, Gielen RCAM, Bakker NAM, Rolfes AL, Garner H, Boeckx B, Traets JJH, Mandjes IAM, de Maaker M, van Brussel T, Chelushkin M, Champanhet E, Lopez-Yurda M, van de Vijver K, van den Berg JG, Hofland I, Klioueva N, Mann RM, Loo CE, van Duijnhoven FH, Skinner V, Luykx S, Kerver E, Kalashnikova E, van Dongen MGJ, Sonke GS, Linn SC, Blank CU, de Visser KE, Salgado R, Wessels LFA, Drukker CA, Schumacher TN, Horlings HM, Lambrechts D, Kok M. Nederlof I, et al. Among authors: hofland i. Nat Med. 2024 Nov;30(11):3223-3235. doi: 10.1038/s41591-024-03249-3. Epub 2024 Sep 16. Nat Med. 2024. PMID: 39284953 Free PMC article. Clinical Trial.
A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in BRAFV600-Mutated Melanoma.
Embaby A, Huijberts SCFA, Wang L, Leite de Oliveira R, Rosing H, Nuijen B, Sanders J, Hofland I, van Steenis C, Kluin RJC, Lieftink C, Smith CG, Blank CU, van Thienen JV, Haanen JBAG, Steeghs N, Opdam FL, Beijnen JH, Huitema ADR, Bernards R, Schellens JHM, Wilgenhof S. Embaby A, et al. Among authors: hofland i. Clin Cancer Res. 2024 Aug 1;30(15):3157-3166. doi: 10.1158/1078-0432.CCR-23-3171. Clin Cancer Res. 2024. PMID: 38739109
A pan-cancer analysis of the microbiome in metastatic cancer.
Battaglia TW, Mimpen IL, Traets JJH, van Hoeck A, Zeverijn LJ, Geurts BS, de Wit GF, Noë M, Hofland I, Vos JL, Cornelissen S, Alkemade M, Broeks A, Zuur CL, Cuppen E, Wessels L, van de Haar J, Voest E. Battaglia TW, et al. Among authors: hofland i. Cell. 2024 Apr 25;187(9):2324-2335.e19. doi: 10.1016/j.cell.2024.03.021. Epub 2024 Apr 9. Cell. 2024. PMID: 38599211 Free article.
Propranolol monotherapy in angiosarcoma - A window-of-opportunity study (PropAngio).
Embaby A, Heinhuis KM, IJzerman NS, Koenen AM, van der Kleij S, Hofland I, van Boven H, Sanders J, van der Graaf WTA, Haas RL, Huitema ADR, van Houdt WJ, Steeghs N. Embaby A, et al. Among authors: hofland i. Eur J Cancer. 2024 May;202:113974. doi: 10.1016/j.ejca.2024.113974. Epub 2024 Mar 2. Eur J Cancer. 2024. PMID: 38452721
CMTM6 shapes antitumor T cell response through modulating protein expression of CD58 and PD-L1.
Miao B, Hu Z, Mezzadra R, Hoeijmakers L, Fauster A, Du S, Yang Z, Sator-Schmitt M, Engel H, Li X, Broderick C, Jin G, Gomez-Eerland R, Rozeman L, Lei X, Matsuo H, Yang C, Hofland I, Peters D, Broeks A, Laport E, Fitz A, Zhao X, Mahmoud MAA, Ma X, Sander S, Liu HK, Cui G, Gan Y, Wu W, Xiao Y, Heck AJR, Guan W, Lowe SW, Horlings HM, Wang C, Brummelkamp TR, Blank CU, Schumacher TNM, Sun C. Miao B, et al. Among authors: hofland i. Cancer Cell. 2023 Oct 9;41(10):1817-1828.e9. doi: 10.1016/j.ccell.2023.08.008. Epub 2023 Sep 7. Cancer Cell. 2023. PMID: 37683639 Free PMC article.
Radiomic signatures from T2W and DWI MRI are predictive of tumour hypoxia in colorectal liver metastases.
Bodalal Z, Bogveradze N, Ter Beek LC, van den Berg JG, Sanders J, Hofland I, Trebeschi S, Groot Lipman KBW, Storck K, Hong EK, Lebedyeva N, Maas M, Beets-Tan RGH, Gomez FM, Kurilova I. Bodalal Z, et al. Among authors: hofland i. Insights Imaging. 2023 Jul 21;14(1):133. doi: 10.1186/s13244-023-01474-x. Insights Imaging. 2023. PMID: 37477715 Free PMC article.
WEE1 inhibitor adavosertib in combination with carboplatin in advanced TP53 mutated ovarian cancer: A biomarker-enriched phase II study.
Embaby A, Kutzera J, Geenen JJ, Pluim D, Hofland I, Sanders J, Lopez-Yurda M, Beijnen JH, Huitema ADR, Witteveen PO, Steeghs N, van Haaften G, van Vugt MATM, de Ridder J, Opdam FL. Embaby A, et al. Among authors: hofland i. Gynecol Oncol. 2023 Jul;174:239-246. doi: 10.1016/j.ygyno.2023.05.063. Epub 2023 May 24. Gynecol Oncol. 2023. PMID: 37236033 Clinical Trial.
57 results